<SEC-DOCUMENT>0001144204-16-094098.txt : 20160413
<SEC-HEADER>0001144204-16-094098.hdr.sgml : 20160413
<ACCEPTANCE-DATETIME>20160413160017
ACCESSION NUMBER:		0001144204-16-094098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160411
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160413
DATE AS OF CHANGE:		20160413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11504
		FILM NUMBER:		161569289

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v436790_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 2pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT TO SECTION 13
OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>April 13, 2016 (April 11, 2016)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CHAMPIONS ONCOLOGY,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: center; font-weight: bold">Delaware</TD>
    <TD STYLE="width: 30%; text-align: center; font-weight: bold">001-11504</TD>
    <TD STYLE="width: 35%; text-align: center; font-weight: bold">52-1401755</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1 University Plaza, Suite 307, Hackensack,
New Jersey 07601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(201) 808-8400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former Address if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 2pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 5.02.</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officer; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 11, 2016,
the Board of Directors (the &ldquo;Board&rdquo;) of Champions Oncology, Inc. (the &ldquo;Company&rdquo;) appointed Dr. Philip Breitfeld
to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Breitfeld has more
than 30 years of experience in oncology. His appointment will further the Company&rsquo;s efforts to accelerate growth and increase
the adoption of its technology platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Breitfeld was most
recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology
Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior
clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst,
where he led oncology development and was Associate Chief Medical Officer. Prior to his career in industry, he held academic positions
at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing
with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology
at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD)
from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has determined
that Dr. Breitfeld satisfies the definition of &ldquo;independent director&rdquo; and the requirements for service on the Company&rsquo;s
Board under the Nasdaq listing standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 8.01</B></TD><TD STYLE="text-align: justify"><B>Other Events</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #1F497D"><FONT STYLE="color: Black">As
stated in our Form 8-K filed on October 29, 2015, on October 28, 2015 we received a notification letter from Nasdaq confirming
our notification to Nasdaq of our non-compliance with Nasdaq Marketplace Rule 5605(b)(1)(A), which requires that our Board consist
of a majority of independent directors.&nbsp; Such non-compliance occurred when a former director of ours did not stand for re-election.&nbsp;
Now, as a result of Mr. Breitfeld&rsquo;s appointment to the Board, the Company has regained compliance with such Nasdaq rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
press release describing the events referenced above is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><I>(d)</I></TD><TD STYLE="text-align: justify"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">The following
exhibit is filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><U>Exhibit
No.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press release dated April 12, 2016</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>CHAMPIONS ONCOLOGY, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">(Registrant)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 49%"><P STYLE="margin: 0pt 0">Date: April 13, 2016</P>


</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%">/s/ Joel Ackerman</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Joel Ackerman<BR>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v436790_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; padding-bottom: 2pt; border-bottom: Black 2pt solid"><IMG SRC="image_001.jpg"></TD>
    <TD STYLE="width: 50%; text-align: right; vertical-align: bottom; padding-bottom: 2pt; border-bottom: Black 2pt solid">NEWS</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #00000A">One University Plaza, Suite
307 Hackensack, NJ 07601 Tel: 201-808-8400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #00000A">For Immediate Release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7DABC3">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #107FC5"><B>Champions Oncology Announces Addition to
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HACKENSACK, N.J., April 12, 2016 -- Champions Oncology, Inc.
(NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more
than 30 years of experience in oncology. His appointment will further the company&rsquo;s efforts to accelerate growth and increase
the adoption of its technology platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. David Sidransky, founder and Chairman of the Board of Directors
commented, &ldquo;We are very excited to have an oncologist of Phil&rsquo;s caliber and experience join our Board of Directors.
Phil has a distinguished career in academia and industry. He has leveraged the depth and breadth of this knowledge of oncology
to become a thought leader in the strategy of oncology drug development. His insights into the strategic issues facing the pharmaceutical
industry and the opportunities for Champions to capitalize on its technology platform will be invaluable to our board conversations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philip Breitfeld, MD was most recently Global Vice President
at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at
Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions
at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development
and was Associate Chief Medical Officer. Prior to his career in industry, he held academic positions at Harvard, University of
Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and
molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber
Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University
of Rochester, and his undergraduate degree (AB in chemistry) from Princeton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Champions Oncology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Champions Oncology, Inc. is engaged in the development of advanced
technology solutions and services to personalize the development and use of oncology drugs. The company&rsquo;s technology platform
is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed
by propagation of the resulting engraftments, or Champions TumorGrafts, in a manner that preserves the biological characteristics
of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction
with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide
the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology
companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs.
TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions&rsquo;
Personalized Oncology Solutions business.<FONT STYLE="font-size: 10pt"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, visit www.championsoncology.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !1 /(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MK(\0>(K;0;8-)^\G<?NX0>3[GT%5&+F^6.Y$ZD:<7*3LC4DD2)"\CJB#JS'
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MBEHH 2BEHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
